Identification of Neuroprognostic Factors for Out-of-hospital Cardiopulmonary Arrest (MIRA29)
NCT06569134
Cardiac Arrest, Cardiovascular Diseases
Brest, France
View Trial DetailsNCT Number: NCT06387225
Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers.
To assess the predictive value of early biomarker testing in patients resuscitated after cardiac arrest, whatever the cause, the investigators plan to conduct a prospective observational multicentre trial.
It is important to bear in mind that the aim of this study is not to assess the long-term prognosis of patients suffering cardiac arrest in order to take measures to limit or discontinue active therapies, but simply to provide a reliable tool, simple and quick to use, in order to be able to identify a sub-population of patients who should be the subject of preferential neuro-protection measures, and conversely to simplify management (moderate temperature control, early cessation of sedation, early extubation) for patients with no neurological lesions.
Interested in participating?
Request Info18 year and older
All sexes
Observational
CHD Vendée, La Roche-sur-Yon, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: at ICU admission
Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90
Time frame: at ICU admission
Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90
Time frame: 90 days after patient enrolment in the study
Determine an assay threshold value admission to the intensive care unit to predict membership of a homogeneous group with favorable neurological outcome at D90
Time frame: at ICU admission
Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission.
Determine the value of combining the two biomarkers at admission.
Time frame: at ICU admission
Determine prognostic value (positive and negative predictive value (PPV/NPV), positive and negative likelihood ratio (LR+/LR-) of each biomarker separately according to the threshold on admission.
Determine the value of combining the two biomarkers at admission.
Time frame: at 4 hours for recovery of effective cardiac activity (RACS)
Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90.
Determine interest of combining the two biomarkers at H4 of the RACS.
Time frame: at 4 hours for recovery of effective cardiac activity (RACS)
Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90.
Determine interest of combining the two biomarkers at H4 of the RACS.
Time frame: 90 days after patient enrolment in the study
Determine a threshold value at H4 for recovery of effective cardiac activity (RACS) to predict membership of a homogeneous group with a favorable neurological outcome at D90.
A score of 0 to 3 is considered a favorable neurological outcome.
Contact information is provided by the study sponsor or research team.
Nantes University Hospital
Other
Acronym: HYPERION-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06569134
Cardiac Arrest, Cardiovascular Diseases
Brest, France
View Trial DetailsNCT00843297
Body Temperature Changes, Cardiac Arrest
Leipzig, Germany
View Trial DetailsNCT07434726
Cardiac Arrest, Cardiovascular Diseases
Bern, Switzerland
View Trial DetailsNCT06672159
Arrhythmias, Cardiac, Cardiac Arrest
Trondheim, Norway
View Trial Details